Intervention: Cilengitide
Trial phase: Phase 2
SMILES: CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 29
Group description: Patients receive cilengitide IV over 1 hour (1800 mg/m2/dose, maximum 75mg/kg) on days 1, 4, 8, 11, 15, 18, 22, and 25. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

cilengitide: Given IV

laboratory biomarker analysis: Correlative studies

pharmacological study: Correlative studies
Eligibility criteria:
Inclusion Criteria:

Histologically confirmed primary central nervous system (CNS) high-grade glioma, including any of the following:

Glioblastoma multiforme
Anaplastic astrocytoma
Anaplastic oligodendroglioma

High-grade astrocytoma not otherwise specified (i.e., anaplastic ganglioglioma, anaplastic mixed glioma, or anaplastic mixed glioneuronal tumors)

No diffuse pontine gliomas, gliomatosis cerebri, and primary spinal cord high-grade astrocytoma
Gliosarcoma
Recurrent or progressive disease that is refractory to standard therapy

Radiographically documented measurable disease

Lesion must be at least twice the thickness of the image from which it is derived (e.g., 10 mm for a 5 mm slice thickness)
No diffuse pontine gliomas
No evidence of prior CNS bleeding
Karnofsky performance status (PS) 50-100% (patients > 16 years of age)
Lansky PS 50-100% (patients =< 16 years of age)
Life expectancy >= 8 weeks
Absolute neutrophil count (ANC) >= 1,000/μL
Platelet count >= 100,000/μL (transfusion independent)
Hemoglobin >= 8.0 g/dL (red blood cell [RBC] transfusions allowed)

Creatinine clearance or radioisotope glomerular filtration rate >= 70mL/min OR serum creatinine based on age/gender as follows:

0.4 mg/dL (1 month to < 6 months of age)
0.5 mg/dL (6 months to < 1 year of age)
0.6 mg/dL (1 to < 2 years of age)
0.8 mg/dL (2 to < 6 years of age)
1.0 mg/dL (6 to < 10 years of age)
1.2 mg/dL (10 to < 13 years of age)
1.5 mg/dL (male) or 1.4mg/dL (female) (13 to < 16 years of age)
1.7 mg/dL (male) or 1.4mg/dL (female) (>= 16 years of age)
Total bilirubin =< 1.5 times upper limit of normal (ULN) for age
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN for age
No evidence of dyspnea at rest
No exercise intolerance
Pulse oximetry > 94%, if determination is clinically indicated
Seizure disorder is allowed provided it is well-controlled with anticonvulsants
No uncontrolled infection
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception
Recovered from all prior therapy
No more than two prior treatments for high-grade glioma (i.e., one initial treatment and one treatment for relapse)
More than 2 weeks since prior myelosuppressive chemotherapy (>= 6 weeks for nitrosoureas)
At least 1 week since prior non-myelosuppressive chemotherapy, immunotherapy, or biologic therapy
At least 2 weeks since prior local palliative radiotherapy (i.e., small port) to a symptomatic non-target lesion only
At least 3 months since prior craniospinal radiotherapy
At least 6 weeks since prior substantial bone marrow radiotherapy

At least 6 months since prior allogeneic stem cell transplant (SCT) or rescue

Patients who have undergone prior allogeneic SCT and who have graft-versus-host disease (GVHD) must have controlled GVHD that is =< grade 2
At least 1 month since prior autologous SCT
More than 1 week since prior growth factors (> 3 weeks for pegfilgrastim [Neulasta®])
No other concurrent anticancer therapy, including chemotherapy or immunomodulating agents
No other concurrent experimental agents or therapies
No concurrent alternative or complimentary therapies
No concurrent homeopathic medicines
No concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) or acetylsalicylic acid (aspirin)
No concurrent steroids as anti-emetics
Concurrent steroids for treatment of increased intracranial pressure allowed if on a stable or decreasing dose for >= 1 week before study entry
Concurrent radiotherapy to localized painful lesions allowed provided >= 1 measurable lesion is not irradiated